News in Brief
Pharmacology - Mar 28
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Pharmacology - Mar 27
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
wire - news in brief
Category
Results 201 - 250 of 380.
Daylight plays an essential role in sleep, alertness and hormone regulation.
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s
APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr
Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results
Climate change not only has an impact on the environment, but also significant effects on global health.
Roche receives CE Mark for its Accu-Chek SugarView app
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di
ClearSpace, a spin-off of EPFL's Space Center (eSpace), has been selected to lead a major European Space Agency (ESA) space debris de-orbiting project with a total budget topping ¤100 million.
Using virtual reality to overcome unconscious biases
Formazione continua e aggiornamento per giuristi: Legge sull'esecuzione e fallimenti (SchKG), Rodrigo Rodriguez Faculty of Economics Seminario IdEP "Dynamic Vertical Foreclosure" - Chiara Fumagalli F
Formazione continua e aggiornamento per giuristi: Legge sull'esecuzione e fallimenti (SchKG), Rodrigo Rodriguez Faculty of Economics Seminario IdEP "Dynamic Vertical Foreclosure" - Chiara Fumagalli F
"100 women and 1000 more": Silvia Santini
Formazione continua e aggiornamento per giuristi: Legge sull'esecuzione e fallimenti (SchKG), Rodrigo Rodriguez Faculty of Economics Seminario IdEP "Dynamic Vertical Foreclosure" - Chiara Fumagalli F
Formazione continua e aggiornamento per giuristi: Legge sull'esecuzione e fallimenti (SchKG), Rodrigo Rodriguez Faculty of Economics Seminario IdEP "Dynamic Vertical Foreclosure" - Chiara Fumagalli F
New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia
ETH Zurich is planning to step up its research activities in Singapore. It aims to extend its current Future Resilient Systems programme by five years and to launch a new programme, Future Health Technologies, in the coming year. On Thursday, 5 December, ETH Zurich announced its future endeavours involving Singapore.
The space telescope CHEOPS is scheduled to begin its journey into space on Tuesday, December 17th on board a Soyuz rocket from the European Space Agency (ESA) in Kourou, French Guiana.
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu
Digital’s doppelganger: The myth of analog media - Towards the "Rethinking Digital Myths" conference
Visiting Alumni: Ktimene Axetell, VP Insights, Arrivalist Visiting Alumni: Valeria Croce, Manager International Relations and Insights, Eurail BV Fall Semester Projects Presentations 2019 Faculty of
Visiting Alumni: Ktimene Axetell, VP Insights, Arrivalist Visiting Alumni: Valeria Croce, Manager International Relations and Insights, Eurail BV Fall Semester Projects Presentations 2019 Faculty of
The space telescope CHEOPS is scheduled to begin its journey into space on Tuesday, December 17th on board a Soyuz rocket from the European Space Agency (ESA) in Kourou, French Guiana.
Switzerland’s influence on European energy policy continues to decline
What would be the consequences of failed negotiations over an electricity agreement between Switzerland and the EU?
What would be the consequences of failed negotiations over an electricity agreement between Switzerland and the EU?
Computer scientist David Dao develops intelligent algorithms that use satellite and drone images of rainforests to predict where the next sites of deforestation will be.
Animal development is a unidirectional process that steers undifferentiated cells of the early embryo into specialized cell types such as brain, muscle or skin cells. Once differentiated, there is almost no way back. A notable exception is the de-differentiation of mature into immature cell types during injured tissue regeneration.
FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today anno
Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today anno
Climate change not only affects the environment, but also has significant consequences on global health.
Proteomics pioneer Ruedi Aebersold is retiring soon. Protein analysis was his life's work, and he paved the way for countless protein researchers around the world.
Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms
Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM
Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM
"100 women and 1000 more": Sara Greco
Causal Effects of Brevity on Style and Success in Social Media Faculty of Informatics Open lecture of the course Argumentation in Conflict Resolution Visiting Alumni: Loredana Padurean, Associate Dean, Asia School of Business «Quel ramo del lago di Como...».
Causal Effects of Brevity on Style and Success in Social Media Faculty of Informatics Open lecture of the course Argumentation in Conflict Resolution Visiting Alumni: Loredana Padurean, Associate Dean, Asia School of Business «Quel ramo del lago di Como...».
Every year, 1.5 million people die from tuberculosis (TB) worldwide. Diagnosis and treatment is particularly difficult in remote rural areas.
Positive phase III results for Roche’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with baseline immunosuppressant therapy Satralizumab targets the interleukin-6 (IL-6) receptor, a potential key driver of neuromyelitis optica spectrum disorder (NMOSD) NMOSD is a rare, debilitating autoimmune disease of the central nervous system that can cause visual impairment, motor disability and even death Roche
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with baseline immunosuppressant therapy Satralizumab targets the interleukin-6 (IL-6) receptor, a potential key driver of neuromyelitis optica spectrum disorder (NMOSD) NMOSD is a rare, debilitating autoimmune disease of the central nervous system that can cause visual impairment, motor disability and even death Roche
ESA Ministerial Council Meeting: Switzerland to participate in new programmes and play a leading role in the removal of space debris
On 27 and 28 November 2019, State Secretary Martina Hirayama attended the European Space Agency's ESA Ministerial Council meeting in Seville ("Space 19+").
On 27 and 28 November 2019, State Secretary Martina Hirayama attended the European Space Agency's ESA Ministerial Council meeting in Seville ("Space 19+").
Anyone who wants to open a bank account or buy a mobile phone plan has to identify themselves to the respective service provider.
The crew of the International Space Station has taken delivery of a haptic interface designed by EPFL spin-off Force Dimension. Astronauts could one day use the device, based on the famous delta robot developed at EPFL by Reymond Clavel, to control unmanned Martian and lunar rovers from afar. In a project called METERON, the European Space Agency (ESA) is exploring how advanced robots could be used to repair satellites in orbit or probe hostile environments like the Martian and lunar surfaces.
News in Brief
Pharmacology - Mar 28
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Pharmacology - Mar 27
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum